NVO
Novo Nordisk A/S
Novo Nordisk A/S historical holders
total: 8
Causeway Capital Management Novo Nordisk A/S transactions over time
- Total transactions:
- 4
- New positions:
- 1
- Added:
- 3
- Held since:
- 2025 Q2
- Held for:
- 4 quarters
- Latest activity:
- 2026 Q1
Sarah Ketterer has been an institutional investor in Novo Nordisk A/S (NVO) since 2025 Q2. According to 2026 Q1 report, Sarah Ketterer holds 1,174,213 shares with a market value of roughly $43.15M representing 0.53% of their equity portfolio. The fund/company first acquired NVO in 2025 Q2, initially purchasing 353,884 shares. Since the initial investment, Causeway Capital Management has made 3 more transactions in this position.
Does Sarah Ketterer still hold NVO?
Yes, Sarah Ketterer continues to hold Novo Nordisk A/S (NVO). According to their 2026 Q1 report, they maintain a position of 1,174,213 shares valued at approximately $43.15M, representing 0.53% of their equity portfolio.
When did Sarah Ketterer first invest in NVO?
Sarah Ketterer first invested in Novo Nordisk A/S (NVO) in 2025 Q2 at the reported quarter-end price of $69.02 per share, acquiring 353,884 shares in their initial purchase.
What is Sarah Ketterer's average cost basis for NVO?
Based on historical transaction data, Sarah Ketterer's estimated cost basis for Novo Nordisk A/S (NVO) is approximately $55.52 per share. This represents their average reported price* across all buy transactions.
Estimated cost basis*
- Weighted AVG buy price:
- $55.52
NVO transactions history by Causeway Capital Management
4 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2026 Q1
|
0.53%
|
1,174,213
|
$36.75
|
$43,152,333
|
+18.15% (+180,363)
|
+0.08%
|
|
2025 Q4
|
0.70%
|
993,850
|
$50.88
|
$50,567,080
|
+42.80% (+297,871)
|
+0.21%
|
|
2025 Q3
|
0.51%
|
695,979
|
$55.49
|
$38,619,855
|
+96.67% (+342,095)
|
+0.25%
|
|
2025 Q2
|
0.39%
|
353,884
|
$69.02
|
$24,425,058
|
new
|
+0.39%
|
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.